RET原癌基因与肿瘤相关性研究的进展现状  

Research Progress on the Relationship Between RET Proto-oncogene and Tumor

作　　者：肖金平 李程 曹云娣 孙志坚 康平 兰晓梅 XIAO Jinping;LI Cheng;CAO Yundi;SUN Zhijian;KANG Ping;LAN Xiaomei(Zhejiang Ketu Medical Technology Co.,Ltd.,Zhejiang Huzhou 313000,China)

机构地区：[1]浙江科途医学科技有限公司,浙江湖州313000

出　　处：《生物技术进展》2022年第1期57-62,共6页Current Biotechnology

基　　金：湖州市攻关计划工业项目(2020C22262)。

摘　　要：RET原癌基因是一种重要的癌症驱动基因,与人类多种肿瘤的发生、发展密切相关。RET相关肿瘤的发病机制包括RET基因激活性点突变与RET基因融合突变。近年来,针对致癌性RET基因融合突变开发的精准靶向药物取得了突破性进展。综述了RET原癌基因与肿瘤发生、发展相关性研究及近年来临床诊疗方面的研究进展,旨在为RET基因突变癌症患者的精准化诊疗提供参考,并通过精准高效地抑制RET基因突变,提高疾病缓解率和控制率。The RET proto-oncogene is an important cancer driver gene,which is closely related to the occurrence and develop-ment of a variety of human tumors.The pathogenesis of RET related tumors includes RET gene activation point mutation and RET gene fusion mutation.In recent years,breakthrough progress has been made in the development of precision targeted drugs for carcinogenic RET gene fusion mutation.In this paper,the research progress of RET related pathogenesis,diagnosis and drug development in recent years were reviewed to provide reference for the accurate diagnosis and treatment of cancer patients with RET gene mutation,and improve the disease remission rate and disease control rate by accurately and efficiently inhibiting RET gene mutation.

关 键 词：RET 融合基因 基因突变 靶向治疗 

分 类 号：R730.2[医药卫生—肿瘤]